SecurityUVE / Universal Insurance Holdings, Inc. (91359V107)
IndustryFire, Marine, and Casualty Insurance
Common Shares Outstanding35,063,424 shares (as of 2018-03-31)
Total Insiders11
Total Directors9
Total Officers4

Stock Insider Trading (from SEC Form 4)

Universal Insurance Holdings, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

UVE / Universal Insurance Holdings, Inc. insiders include DOWNES SEAN P, PALMIERI RALPH J., Callahan Scott P., and Lewis Darryl L., Donaghy Stephen, Springer Jon, WILENTZ JOEL, SCHINDLER OZZIE A, PETERSON RICHARD D, Wilcox Frank PIETRANGELO MICHAEL, .

Insider Roster

Insider Dir Off 10% Shares Owned
Springer Jon President and CRO, Director
X X 496,725
Wilcox Frank CFO, Principal Acct. Officer
X 132,324
PALMIERI RALPH J. Director
X 15,698
DOWNES SEAN P CEO, Director
X X 1,499,141
SCHINDLER OZZIE A Director
X 21,424
PETERSON RICHARD D Director
X 1,065
Callahan Scott P. Director
X 8,536
PIETRANGELO MICHAEL Director
X 80,763
Donaghy Stephen COO
X 468,607
WILENTZ JOEL Director
X
Lewis Darryl L. Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-17 4 Springer Jon S D 35.344 -18,926 496,725 17,556,248
2018-05-03 4 Wilcox Frank S D 32.3606 -14,000 132,324 4,282,084
2018-05-02 4 PALMIERI RALPH J. F D 32.9 -18,319 15,698
2018-05-02 4 PALMIERI RALPH J. M D 20.09 30,000 34,017
2018-05-01 4 DOWNES SEAN P S D 32.776 -50,000 1,499,141 49,135,845
2018-05-01 4 SCHINDLER OZZIE A S D 33 -34,076 21,424 706,992
2018-04-30 4 SCHINDLER OZZIE A S D 33.01 -500 55,500 1,832,055
2018-04-09 4 PETERSON RICHARD D By The RDP Revocable Trust dated August 11, 2011 F I 30.85 -515 1,065
2018-04-09 4 PETERSON RICHARD D By The RDP Revocable Trust dated August 11, 2011 M I 19.85 800 1,580
2018-04-04 4 Springer Jon F D 32.25 -147,119 515,651
2018-04-04 4 Springer Jon M D 19.52 22,333 662,770
2018-04-04 4 Springer Jon M D 19.52 165,016 640,437
2018-03-20 4 DOWNES SEAN P F D 32.7 -475,174 1,549,141
2018-03-20 4 DOWNES SEAN P M D 19.52 300,000 2,024,315
2018-03-20 4 DOWNES SEAN P M D 19.52 133,334 1,724,315
2018-03-20 4 DOWNES SEAN P M D 24.18 175,000 1,590,981
2018-02-23 4 PIETRANGELO MICHAEL S D 30.244 -16,955 80,763 2,442,596
2018-02-23 4 Callahan Scott P. S D 30.526 -2,600 8,536 260,570
2018-02-22 4 Callahan Scott P. F D 30.85 -3,864 11,136
2018-02-22 4 Callahan Scott P. M D 11.92 10,000 15,000
2018-02-22 4 Wilcox Frank A D 50,000 146,324
2018-02-08 4 PIETRANGELO MICHAEL F D 29.1 -6,974 97,718
2018-02-08 4 PIETRANGELO MICHAEL M D 4.51 45,000 104,692
2018-01-22 4 DOWNES SEAN P F D 30 -26,953 1,415,981
2018-01-22 4 DOWNES SEAN P M D 73,529 1,442,934
2018-01-22 4 Springer Jon F D 30 -7,500 475,421
2018-01-22 4 Springer Jon M D 24,510 482,921
2018-01-02 4 Springer Jon F D 27.3 -2,643 458,411
2018-01-02 4 Springer Jon M D 7,190 461,054
2018-01-02 4 DOWNES SEAN P F D 27.3 -6,126 1,369,405
2018-01-02 4 DOWNES SEAN P M D 21,570 1,375,531
2017-11-28 4 PIETRANGELO MICHAEL S D 26.2692 -9,969 59,692 1,568,061
2017-11-20 4 Donaghy Stephen F D 26.35 -79,462 468,607
2017-11-20 4 Donaghy Stephen M D 8.01 133,333 548,069
2017-11-17 4 DOWNES SEAN P F D 25.95 -119,736 1,403,961
2017-11-17 4 DOWNES SEAN P M D 8.01 200,000 1,523,697
2017-11-10 4 Springer Jon F D 25.25 -171,857 453,864
2017-11-10 4 Springer Jon M D 7.33 200,000 625,721
2017-11-10 4 Springer Jon M D 4.51 66,667 425,721
2017-09-08 4 Wilcox Frank P D 17.65 300 96,324 1,700,119
2017-09-08 4 Wilcox Frank P D 17.7 1,700 96,024 1,699,625
2017-07-10 4 PIETRANGELO MICHAEL A D 25,413 69,661
2017-01-23 4 WILENTZ JOEL F D 26.8 -7,573 228,623
2017-01-23 4 WILENTZ JOEL M D 4.51 45,000 236,196
2017-01-09 4 Springer Jon F D 28.75 -9,835 359,054
2017-01-09 4 Springer Jon M D 28,761 368,889
2017-01-09 4 DOWNES SEAN P F D 28.75 -31,328 1,323,697
2017-01-09 4 DOWNES SEAN P M D 86,281 1,355,025
2016-12-12 4 PIETRANGELO MICHAEL S D 25.65 -17,000 44,248 1,134,961
2016-12-07 4 Donaghy Stephen F D 25.65 -30,000 400,512
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Universal Expects Mid-Year Reinsurance Renewal Pricing To Be Lower

2018-05-01 seekingalpha
The mid-year reinsurance renewal at June 1st is expected to yield pricing that is lower than last year for Florida-headquartered primary insurance company Universal Insurance Holdings (NYSEMKT:UVE), which expects to be able to keep its retention static, while buying more coverage at comparable or lower rates. (9-0)

BRIEF-Universal Insurance CEO Sean Downes's FY 2017 Total Compensation Was $19.3 Million

2018-04-27 reuters
* UNIVERSAL INSURANCE HOLDINGS INC - CEO SEAN DOWNES'S FY 2017 TOTAL COMPENSATION WAS $19.3 MILLION VERSUS $16.3 MILLION IN FY 2016 - SEC FILING Source text for Eikon: (bit.ly/2KkM5RB) Further company coverage: (9-1)

Universal Insurance Holdings' (UVE) CEO Sean Downes on Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
Universal Insurance Holdings, Inc (NYSEMKT:UVE) Q1 2018 Results Conference Call April 25, 2018 10:00 AM ET (9-0)

Universal Insurance Holdings' (UVE) CEO Sean Downes on Q4 2017 Results - Earnings Call Transcript

2018-02-21 seekingalpha
Universal Insurance Holdings, Inc (NYSEMKT:UVE) Q4 2017 Earnings Conference Call February 21, 2018 10:00 AM ET (9-0)

An 'All-Weather' Income Portfolio For Financial Independence

2018-01-21 seekingalpha
Over the past year I have set out to turn profits from the aging bull market into a stable, incoming-producing portfolio for financial independence. (129-3)